Opko Health (OPK)

NASDAQ
Currency in USD
1.340
-0.020(-1.47%)
Real-time Data·
OPK Scorecard
Full Analysis
Management has been aggressively buying back shares
OPK is not included in our AI-picked strategies. See which stocks are.
Fair Value
Day's Range
1.3401.375
52 wk Range
1.2102.035
Key Statistics
Edit
Prev. Close
1.36
Open
1.35
Day's Range
1.34-1.375
52 wk Range
1.21-2.035
Volume
457.37K
Average Volume (3m)
3.19M
1-Year Change
3.03%
Book Value / Share
1.95
Fair Value
unlockUnlock
Fair Value Upside
unlockUnlock
OPK Scorecardpro icon
Company’s Health
Unlock
Fair Value
Unlock Price
Fair Price
Upside
Price Target
3.992
Upside
+197.89%
Members' Sentiments
Bearish
Bullish
ProTips
Quickly burning through cash

Opko Health Inc News & Analysis

Show more

Technical Analysis

Summary
Strong Sell
Sell
Neutral
Buy
Strong Buy
Strong Sell
Technical Indicators
Strong Sell
Moving Averages
Sell

Opko Health Company Profile

OPKO Health, Inc., a healthcare company, engages in the diagnostics and pharmaceuticals businesses in the United States, Ireland, Chile, Spain, Israel, Mexico, and internationally. The company’s Diagnostics segment operates BioReference Laboratories that offer laboratory testing services for the detection, diagnosis, evaluation, monitoring, and treatment of diseases, including esoteric testing, molecular diagnostics, anatomical pathology, genetics, women’s health, and correctional healthcare to physician offices, clinics, hospitals, employers, and governmental units; and 4Kscore prostate cancer test services. Its Pharmaceutical segment offers Rayaldee to treat secondary hyperparathyroidism in adults with stage 3 or 4 chronic kidney disease, and vitamin D insufficiency. This segment also develops multi-specific immune therapies focused on oncology, immunology, and infectious diseases; OPK88004, an orally administered selective androgen receptor modulator; OPK88003, a once-weekly administered peptide for the treatment of type 2 diabetes and related obesity; Somatrogon (hGH-CTP), a once-weekly human growth hormone injection; and Factor VIIa-CTP, a novel long-acting coagulation factor to treat hemophilia. In addition, it develops and commercializes longer-acting proprietary versions of already approved therapeutic proteins or peptides; develops and produces specialty APIs; develops, manufactures, markets, and sells pharmaceutical, nutraceutical, veterinary, and ophthalmic products; commercializes food supplements and over the counter products; manufactures and sells products primarily in the generics market; and markets, distributes, and sells pharmaceutical products for a range of indications, including cardiovascular products, vaccines, antibiotics, gastro-intestinal products, hormones, and others. The company also operates pharmaceutical platforms in Spain, Ireland, Chile, and Mexico. OPKO Health, Inc. was founded in 2007 and is headquartered in Miami, Florida.

Opko Health Inc Earnings Call Summary for Q1/2025

  • Opko Health reported Q1 2025 EPS of -$0.10, missing -$0.09 forecast; revenue at $149.9M, below $163.14M estimate; stock fell 5.8% after-hours
  • Net loss narrowed to $67.6M from $81.8M in Q1 2024; company maintains $450M cash position; strategic asset sales and cost reductions underway
  • 2025 revenue guidance: $675M-$685M; costs/expenses: $825M-$875M; focus on oral GLP-1/glucagon tablet for NASH and obesity
  • Challenges: Inflation Reduction Act pressuring RAYALDEE sales; foreign currency impacts on pharmaceutical segment; profitability dependent on cost management
  • Analyst price targets range $2.00-$8.50 per share; executives believe shares 'significantly undervalued'; InvestingPro rates financial health as 'Fair'
Last Updated: 30/04/2025, 22:28
Read Full Transcript

Compare OPK to Peers and Sector

Metrics to compare
OPK
Peers
Sector
Relationship
P/E Ratio
−27.7x−0.2x−0.5x
PEG Ratio
−0.33−0.010.00
Price/Book
0.8x1.3x2.6x
Price / LTM Sales
1.6x1.2x3.1x
Upside (Analyst Target)
120.6%42.0%45.7%
Fair Value Upside
Unlock15.9%5.7%Unlock

Analyst Ratings

6 Buy
0 Hold
0 Sell
Ratings:
6 analysts
Overall Consensus
Buy

Analysts 12-Month Price Target:

Average 3.992
(+197.89% Upside)

Earnings

Latest Release
Apr 30, 2025
EPS / Forecast
-0.10 / -0.09
Revenue / Forecast
149.90M / 163.14M
EPS Revisions
Last 90 days

People Also Watch

133.55
NBIX
-1.02%
17.95
ODP
-3.34%
55.95
NYT
-0.76%
1.075
LXRX
-4.87%
109.92
JAZZ
-2.28%

FAQ

What Is the Opko Health (OPK) Share Price Today?

The live Opko Health share price today is 1.34.

What Stock Exchange Does Opko Health (OPK) Trade On?

Opko Health is listed and trades on the Nasdaq Stock Exchange stock exchange.

What Is the Ticker (Stock Symbol) for Opko Health?

The stock symbol (also called a 'ticker') for Opko Health is "OPK."

What Is the Current Opko Health Market Cap?

As of today, Opko Health market capitalisation is 1.08B.

What Is Opko Health's (OPK) Earnings Per Share (TTM)?

The Opko Health EPS -0.06 (Trailing Twelve Months).

When Is the Next Opko Health Earnings Date?

Opko Health's next earnings report will be released on 30 Jul 2025.

Is OPK a Buy or Sell From a Technical Analyst Perspective?

Based on today's Opko Health moving averages and other technical indicators, the daily buy/sell signal is Neutral.

How Many Times Has Opko Health Stock Split?

Opko Health has split 0 times. (See the OPK stock split history page for full effective split date and price information.)

How Many Employees Does Opko Health Have?

Opko Health currently has 2997 employees.

What is the current trading status of Opko Health (OPK)?

As of 11 Jul 2025, Opko Health (OPK) is trading at a price of 1.34, with a previous close of 1.36. The stock has fluctuated within a day range of 1.34 to 1.38, while its 52-week range spans from 1.21 to 2.04.
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2025 - Fusion Media Limited. All Rights Reserved.